<DOC>
	<DOC>NCT00351832</DOC>
	<brief_summary>This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg bid or 100mg qd compared to placebo in patients with type 2 diabetes.</brief_summary>
	<brief_title>A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosis of type 2 diabetes Patients who have been placed on dietary therapy/exercise therapy without achievement of glycemic control Outpatients Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes Significant cardiovascular disease Significant diabetic complications Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Hemoglobin A1c</keyword>
</DOC>